Arthurian Life Sciences

Verona Pharma is a clinical-stage biopharmaceutical company based in London, established in 2005. The company specializes in developing and commercializing therapies for respiratory diseases that have significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is being developed in various formulations, including nebulized, dry powder inhaler, and pressurized metered-dose inhaler, with the nebulized form currently in Phase 2b clinical development for the maintenance treatment of COPD. Verona Pharma's commitment is to enhance the health and quality of life for individuals suffering from chronic respiratory conditions through innovative therapeutic solutions.

Rutherford Health Plc is a provider of cancer care services in the United Kingdom, operating a network of oncology centers known as Rutherford Cancer Centres. The company offers a comprehensive range of treatments, including proton beam therapy, radiotherapy, chemotherapy, immunotherapy, and various diagnostic services such as computerized tomography and magnetic resonance imaging. It caters to private patients with medical insurance, self-pay patients, and individuals referred by the National Health Service. Founded in 2015 and based in Hereford, Rutherford Health also engages in development and infrastructure activities to enhance its service offerings. The company has established a strategic collaboration with Panthera Biopartners to further advance its capabilities in cancer treatment.

Apitope is a biotechnology company dedicated to the discovery and development of disease-modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves' disease, and uveitis. The company specializes in creating antigen-specific therapeutic peptides that directly target the underlying causes of these conditions. Apitope's innovative approach aims to provide effective treatments that enhance patients' quality of life while minimizing the risk of secondary infections and complications. The company's first product candidate is licensed to Merck Serono, and it continues to advance its remaining portfolio of product candidates developed through its proprietary platform technology.

CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

Sphere Medical Holding plc, established in 2001 and headquartered in Cardiff, UK, specializes in developing and selling medical monitoring and diagnostic equipment. The company's primary product, the Proxima solution, measures blood gases, electrolytes, and metabolites, aiding in the care of critically ill and unstable patients. Sphere Medical's innovative products, including microanalyser platforms and various monitoring systems, provide healthcare professionals with real-time data to optimize patient outcomes. The company operates in the UK, Europe, and Japan.

Interrad Medical is a medical device company located in Plymouth, Minnesota. The company was founded by Dr. Michael Rosenberg, a practicing interventional radiologist, in collaboration with several other highly regarded physicians. The company's mission is the development and commercialization of innovative medical devices for use in minimally invasive interventional and surgical procedures. Interrad Medical has an experienced market-proven team with a successful track record of bringing devices through development to commercialization. it has a robust product portfolio targeting minimally invasive vascular and surgical procedures. These devices are designed to solve unmet medical needs and serve large, growing patient populations.

MedaPhor Limited, an e-learning company, produces training products for postgraduate medical professionals. The company offers tutorials for learning or improving ultrasound examination techniques; and simulation technology solutions for medical education and training. Its solutions include Blue Phantom, which offers ultrasound phantoms for hands-on gynaecological and obstetrics simulation training; True Anatomy, an endovaginal training model for ultrasound simulation training; and intrauterine pregnancy, ectopic pregnancy, and general pathology models. The company was incorporated in 2004 and is based in Cardiff, the United Kingdom.

ReNeuron Group is a biotechnology company based in Pencoed, United Kingdom, specializing in the research and development of cell-based therapies for various medical conditions. Founded in 1997, it is primarily focused on developing innovative treatments for stroke disability and inherited retinal diseases, including its CTX stem cell therapy candidate, which is currently undergoing Phase IIb clinical trials, and its human retinal progenitor cell therapy, which is in Phase I/IIa trials for retinitis pigmentosa. The company is also exploring the therapeutic potential of CTX-derived exosomes, which are nano-sized packages of information released by CTX cells. Additionally, ReNeuron has established a research agreement with a U.S. biotechnology firm to collaborate on novel gene silencing-based therapeutics. Through its advanced product pipeline and strategic partnerships, ReNeuron aims to address significant unmet medical needs in the therapeutic landscape.